Phone App and Cream Demonstration for Children With Atopic Dermatitis
Tests a phone app and cream demonstration in children with eczema.
Plain-language title generated from the registry record
Registry title: Topical Treatment for Atopic Dermatitis
Key facts
- Where
- Winston-Salem, United StatesSee the site
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT06244212
- Record updated
- 4 August 2026
- Original description
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.Read full original descriptionShow less
Topical Treatment for Atopic Dermatitis
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.
Inclusion: Diagnosis of skin dermatitis; Age > 9; Ability to return for a one-week clinical studies follow-up; Patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study); Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology.
Exclusion: Patients without the diagnosis of skin dermatitis; Inability to return for a one week follow up appointment; Body Surface Area (BSA) affected <2%.